A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Public ClinicalTrials.gov record NCT04245839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This study is divided into three periods: * Pretreatment, which consists of screening assessments, leukapheresis and the Pretreatment evaluation; * Treatment, which starts with the administration of lymphodepleting (LD) chemotherapy and continues through JCAR017 administration at Day 1 with follow-up through Day 29; * Posttreatment, which includes follow-up assessments for disease status and safety for 5 years.
Study identification
- NCT ID
- NCT04245839
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 276 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 13, 2020
- Primary completion
- Sep 29, 2031
- Completion
- Sep 29, 2031
- Last update posted
- Nov 4, 2025
2020 – 2031
United States locations
- U.S. sites
- 23
- U.S. states
- 19
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 111 | Santa Monica | California | 90095 | — |
| Local Institution - 107 | Aurora | Colorado | 80045 | — |
| Local Institution - 105 | New Haven | Connecticut | 06520 | — |
| Local Institution - 103 | Chicago | Illinois | 60611 | — |
| Local Institution - 109 | Niles | Illinois | 60714 | — |
| Local Institution - 122 | Iowa City | Iowa | 52242 | — |
| Local Institution - 124 | Wichita | Kansas | 67124 | — |
| Local Institution - 102 | Baltimore | Maryland | 21201 | — |
| Local Institution - 100 | Boston | Massachusetts | 02114 | — |
| Local Institution - 101 | Boston | Massachusetts | 02215 | — |
| Local Institution - 127 | Detroit | Michigan | 48201 | — |
| Local Institution - 123 | Morristown | New Jersey | 07960 | — |
| Local Institution - 116 | New York | New York | 10021 | — |
| Local Institution - 110 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 112 | Cleveland | Ohio | 44195 | — |
| Local Institution - 114 | Portland | Oregon | 97213 | — |
| Local Institution - 117 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 113 | Sioux Falls | South Dakota | 57105 | — |
| Local Institution - 121 | Dallas | Texas | 75230-2510 | — |
| Local Institution - 104 | Houston | Texas | 77030 | — |
| Local Institution - 119 | Houston | Texas | 77030 | — |
| Local Institution - 115 | Charlottesville | Virginia | 22903 | — |
| Local Institution - 108 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04245839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2025 · Synced Sep 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04245839 live on ClinicalTrials.gov.